Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Apr 10, 2025 · Filed Apr 14, 2025
The CFO of Humacyte paid $31K out of pocket for Humacyte shares. 5 other people at Humacyte bought some too, in the same month. Shares held went up 97% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$30,600
Shares × reported transaction price
$25K–$100K
+97.1%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
6 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 4.5% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2024 ($678K)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-28. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
13 days after results of Mar 28, 2025, 33 days before results of May 13, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −11.0% | −1.9% | −9.1% |
| 30 days | +22.7% | +9.8% | +12.9% |
| 90 days | +60.4% | +16.2% | +44.2% |
| 180 days | +14.3% | +23.3% | −9.0% |
| 365 days | −52.2% | +30.2% | −82.4% |
Past results only. Not a forecast.
Insider buying
Traded Apr 14, 2025 · filed 1 day later
Humacyte's Chief Commercial Officer paid $10K out of pocket for Humacyte shares. 5 other people at Humacyte bought some too, in the same month. Shares held went up 42% with this purchase.
Insider buying
Traded Apr 10, 2025 · filed 4 days later
Humacyte's Chief Medical Officer paid $12K out of pocket for Humacyte shares. 5 other people at Humacyte bought some too, in the same month.
Insider buying
Traded Apr 7, 2025 · filed 1 day later
A Humacyte director paid $20K out of pocket for Humacyte shares. 5 other people at Humacyte bought some too, in the same month. Shares held went up 94% with this purchase.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.